Overall verdict
Buy
6.7/10
1-year performance
+10.77%
Score breakdown
Up 10.8% over 1 year, 83% of the 52-week range.
Strongest: Growth 10.0/10. Weakest: Shareholder return 2.9/10.
9 analysts.
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers ; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers ;
SYLVANT for the treatment of adult patients with multicentric castleman disease ; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer ; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor ; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK ;
BG-60366, an EGFR-targeted CDAC ; BG-89894 (SYH2039), a MAT2A Inhibitor ; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor ; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody ; BGB-26808, a HPK-1 Inhibitor ; BGB-C354, an anti-B7H3 ADC ; Zanidatamab, a bispecific HER2-targeted antibody ; BG-C137, an anti-FGFR2b ADC ; BGB-53038, a Pan-KRAS Inhibitor ; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody ;
BGB-B3227, an anti-MUC1xCD16A bispecific antibody ; BG-C477, an anti-CEAADC ; BGB-43395, a CDK4 Inhibitor ; BG-68501, a CDK2 Inhibitor ; BG-C9074, an anti-B7H4 ADC ; BGB-21447, a Bcl-2 Inhibitor ; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.
Sector
Health Care
Industry
Biotechnology
Primary listing
Nasdaq
Switzerland
CEO
John Oyler
Founded
2010
Employees
12 000
Revenue / employee
446 430 USD
Next earnings
November 6, 2026 (estimated)
Institutional holders
- BAKER BROS. ADVISORS LP7.77%
- PRIMECAP MANAGEMENT CO/CA/4.42%
- Capital International Investors3.72%
- FMR LLC2.19%
- Capital World Investors1.99%
- CITADEL ADVISORS LLC1.26%
- Temasek Holdings (Private) Ltd0.75%
- PRICE T ROWE ASSOCIATES INC /MD/0.67%
- BlackRock, Inc.0.61%
- Other institutions7.38%
- Rest of the register69.25%
282 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
385.22 USD
52-week low
253.95 USD
1-year performance
10.77%
Rising
Year-to-date performance
19.55%
Rising
Drawdown
-5.76%
Mild pullback
Position in the 52-week range
83% of range
Against the world ETF
Over 11 years, from February 2016 to August 2026, the share did not do better than the world ETF once risk is accounted for. It earned more, but shaking 3.9 times harder: for the risk taken, the ETF paid better.
10,000 € placed at the end of February 2016 are worth today
| BeOne Medicines | 117 530 € |
| World ETF | 35 657 € |
| S&P 500 | 44 970 € |
| Risk-free placement | 10 918 € |
The risk
- Shaking:the share moves 3.9 times as much as the world ETF.
- Worst fall:-67 % between September 2021 and May 2022. 10,000 € placed at the top fell to 3 332 €. The world ETF, at worst: -34 %. The share has not returned to its high yet.
BeOne Medicines earned 3 times as much as the world ETF since 2016
Value of 10,000 euros placed at the end of February 2016, dividends reinvested, in euros
- BeOne Medicines: 117 530 €
- World ETF: 35 657 €
- S&P 500: 44 970 €
- Risk-free placement: 10 918 €
Share price without dividends; the world ETF and the index reinvest theirs. A dividend payer is therefore understated here.
Based on past performance. This is not a recommendation.
Range: 168.46 USD - 185.49 USD (comparables only)
The price implies growth of 10.66% per year; the company grows at 25.00%.
Gross margin 86.8%, net margin 10.7%, ROIC 12.1%, ROE 14.7%.
Net margin
10.70%
Fair
Sector -15.62%|S&P 12.97%
Gross margin
86.76%
High
Return on equity (ROE)
14.70%
Fair
Sector -19.73%|S&P 16.52%
Return on invested capital (ROIC)
12.07%
Fair
Free cash flow margin (FCF)
21.70%
High
Profit-to-cash conversion (FCF conversion)
2.03x
Exceptional
Margin stability
3298.3 pts
Very uneven
Revenue to net income
Growth
10.0/10Revenue up 29.4% over 1 year, 76.9% a year over 5.
Revenue (trailing 12 months)
6.1Md USD
Revenue growth (1y)
29.39%
Hyper-growth
Revenue growth (3y)
278.80%
Hyper-growth
EPS growth (1y)
143.77%
Hyper-growth
EPS CAGR (5y)
—
EPS revisions (3 months)
15.35%
Sharply revised up
Valuation
5.4/10P/E 63.8x, forward P/E 47.6x, EV/EBITDA 34.2x, PEG 0.44.
P/E (TTM)
63.8x
Very expensive
Sector 29.6x|S&P 23.0x
Forward P/E
47.6x
Expensive
EV / EBITDA
34.2x
Expensive
Sector 23.2x|S&P 14.5x
PEG
0.44
Growth unpriced
Sector 1.05|S&P 0.86
Fair value (reverse DCF)
176.97 USD
Deeply overvalued
Market cap
41.1Md USD
Financial strength
9.4/10Cash covers 256.6% of the debt, net debt/EBITDA -4.4x.
Net debt / EBITDA
-4.4x
Net cash
Gearing (net debt / equity)
-62.03%
Net cash
Cash
5.3Md USD
Cash / market cap
12.79%
Solid
Cash / total debt
256.60%
Net cash
Interest coverage
9.5x
Solid
Net debt
-3.2Md USD
Equity
5.2Md USD
Closed daily candles, 2 years
Last close on September 24, 2026: 359.97 USD
- MM20357.13
- MM50347.90
- MM200318.81
- RSI 1453.7
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+0.45%
200-day average slope, 3 months
+0.53%
50-day average slope, 1 month
+9.20%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
1.64 % per day
Volatility change
-14.73%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 7.63 (14) | 7.60 (16) | 6 750 (32) | 1 233 (16) | 849 (25) |
| 2027 | 10.09 (16) | 10.32 (17) | 7 720 (34) | 1 675 (16) | 1 175 (28) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 21, 2026.
Same sub-industry: 431 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ARGX | 7.5 | 6.9 | 59.5Md USD | 36.9x | 32.8 % | 81.8 % | 23.3 % | -4.1x | 1.9 % | 33.9 % | ||
| 2 | ONC | 6.7 | 6.7 | 41.1Md USD | 63.8x | 10.7 % | 29.4 % | 12.1 % | -4.4x | 3.2 % | 10.8 % | ||
| 3 | VRTX | 6.7 | 5.9 | 131Md USD | 30.0x | 34.7 % | 12.0 % | 21.5 % | -0.9x | 2.9 % | 38.4 % | ||
| 4 | REGN | 6.6 | 6.0 | 82.6Md USD | 19.8x | 27.9 % | 16.7 % | 13.0 % | -1.3x | 4.6 % | 40.2 % | ||
| 5 | AMGN | 6.3 | 6.2 | 220Md USD | 25.2x | 22.9 % | 9.8 % | 14.0 % | 2.9x | 4.6 % | 42.2 % | ||
| 6 | ABBV | 6.2 | 5.6 | 468Md USD | 74.9x | 9.7 % | 10.2 % | 10.5 % | 2.2x | 3.9 % | 19.4 % | ||
| 7 | GILD | 5.5 | 4.3 | 188Md USD | Not meaningful (loss) | -10.6 % | 10.7 % | -8.4 % | 1.1x | 6.9 % | 31.0 % | ||
| 8 | CSL | 4.5 | 4.2 | 60.5Md USD | Not meaningful (loss) | -15.6 % | -2.8 % | -8.9 % | 1.8x | 4.7 % | -9.7 % | ||
| 9 | MRNA | 2.7 | 1.9 | 72.7Md USD | Not meaningful (loss) | -141.4 % | 2.1 % | -34.8 % | 1.3x | -1.7 % | 654.5 % |
